Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 10/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28465215 | 0.86 | ELANE (0.43) | ELANE | |
| SCHEMBL22978450 | 0.84 | ELANE (0.39) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL22988835 | 0.82 | MTNR1A (0.40) | L3MBTL1BRD4HSP90AA1HSP90AB1PDE10A | |
| SCHEMBL22988839 | 0.82 | L3MBTL1 (0.38) | L3MBTL1BRD4HSP90AA1HSP90AB1HTR6 | |
| SCHEMBL4505573 | 0.80 | L3MBTL1 (0.39) | L3MBTL1ELANEBRD4DTYMKEPHX1 | |
| SCHEMBL4569771 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ELANEBRD4DTYMKEPHX1 | |
| SCHEMBL30940044 | 0.80 | L3MBTL1 (0.47) | L3MBTL1ELANEBRD4DTYMKEPHX1 | |
| SCHEMBL3705482 | 0.80 | L3MBTL1 (0.47) | L3MBTL1ELANEBRD4DTYMKEPHX1 | |
| SCHEMBL22988838 | 0.80 | BRD4 (0.36) | L3MBTL1BRD4HTR6 | |
| SCHEMBL14197023 | 0.79 | L3MBTL1 (0.38) | L3MBTL1ELANEBRD4DTYMKEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018233526-A9 | CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2018233526-A9 | CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | L3MBTL1 4459/4885ELANE 3539/4885BRD4 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.